Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Preventing Postoperative Immunosuppression by Inhibition of PI3K in Surgery-Induced Myeloid Derived Suppressor Cells

EF 2020-21

Résumé
Surgery is a necessary treatment for patients with solid tumors. However, data shows that surgery leads to a weakened immune system which can contribute to the worst-case scenario of the tumour reappearing and spreading throughout the patient's body. Natural killer (NK) cells can act as defenders against cancer as they survey the body and destroy any cancer cells that appear before they can develop into solid tumours. Although the importance of NK cells in controlling tumour growth is well known, our research has shown that surgery dramatically hinder their ability to recognize and eradicate tumour cells. Unfortunately, there is no current therapy for treating the suppression in NK cell activity which occurs following surgery and new approaches targeting this critical stage may hold the potential for reversing this immune suppression. We have shown that following surgery, a large number of cells that contain the ability to suppress NK cells are produced by the body, called myeloid derived suppressor cells (MDSCs). Targeting these MDSCs in patients may provide an effective treatment against the immune suppressive effects of surgery. To accomplish this goal, we have attempted to identify ways of shutting down MDSC activity without harming beneficial cells in the body. We have found a distinct identifier present only on MDSCs which we have used to deliver a drug to inhibit their suppressive activity to restore the NK cells' tumour-fighting ability. The current goal is to answer whether this strategy would be safe and effective before using it on cancer surgery patients. We hope that our efforts will one day help eliminate the risk of cancer recurrence for patients who undergo surgery for tumour removal.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
449439
Name
Tennakoon Mudiyansel Gayashan
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Preventing Postoperative Immunosuppression by Inhibition of PI3K in Surgery-Induced Myeloid Derived Suppressor Cells
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Flow Cytometry; Immunosuppression; Immunotherapy; Natural Killer Cells; Pi3k; Surgery
Abstract
Surgery is a necessary treatment for patients with solid tumors. However, data shows that surgery leads to a weakened immune system which can contribute to the worst-case scenario of the tumour reappearing and spreading throughout the patient's body. Natural killer (NK) cells can act as defenders against cancer as they survey the body and destroy any cancer cells that appear before they can develop into solid tumours. Although the importance of NK cells in controlling tumour growth is well known, our research has shown that surgery dramatically hinder their ability to recognize and eradicate tumour cells. Unfortunately, there is no current therapy for treating the suppression in NK cell activity which occurs following surgery and new approaches targeting this critical stage may hold the potential for reversing this immune suppression. We have shown that following surgery, a large number of cells that contain the ability to suppress NK cells are produced by the body, called myeloid derived suppressor cells (MDSCs). Targeting these MDSCs in patients may provide an effective treatment against the immune suppressive effects of surgery. To accomplish this goal, we have attempted to identify ways of shutting down MDSC activity without harming beneficial cells in the body. We have found a distinct identifier present only on MDSCs which we have used to deliver a drug to inhibit their suppressive activity to restore the NK cells' tumour-fighting ability. The current goal is to answer whether this strategy would be safe and effective before using it on cancer surgery patients. We hope that our efforts will one day help eliminate the risk of cancer recurrence for patients who undergo surgery for tumour removal.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tennakoon Mudiyansel, Gayashan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~